HIV-1 nef in macrophage-mediated disease pathogenesis

International Reviews of Immunology

Volumn 31, Issue 6, 2012, Pages 432-450

  Lamers, Susanna L ^a   Fogel, Gary B ^b   Singer, Elyse J ^c,d   Salemi, Marco ^e   Nolan, David J ^e   Huysentruyt, Leanne C ^f   McGrath, Michael S ^g,h  

^a BIOINFOEXPERTS LLC   (United States)

^b NATURAL SELECTION INC   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d National Neurological AIDS Bank   (United States)

^e UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g AIDS and Cancer Specimen Resource   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cardiovascular disease; Dementia; HIV 1 lymphoma; Macrophages; Nef

Indexed keywords

NEF PROTEIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CD4 LYMPHOCYTE COUNT; GENETIC VARIABILITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED DEMENTIA; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNE RESPONSE; LYMPHOMA; MACROPHAGE FUNCTION; METABOLIC DISORDER; PRIORITY JOURNAL; REVIEW;

ANIMALS; DISEASE PROGRESSION; HIV INFECTIONS; HIV-1; HOST-PATHOGEN INTERACTIONS; HUMANS; MACROPHAGES; MUTATION; NEF GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; POLYMORPHISM, GENETIC; SIGNAL TRANSDUCTION; VIRUS REPLICATION;

EID: 84870951604     PISSN: 08830185     EISSN: 15635244     Source Type: Journal    
DOI: 10.3109/08830185.2012.737073     Document Type: Review

References (185)

1. Richman DD, Little SJ, Smith DM, et al. HIV evolution and escape. Trans Am Clin Climatol Assoc 2004;115:289-303.
2. Le Douce V, Herbein G, Rohr O, Schwartz C. Molecular mechanisms of HIV-1 persistence in the monocyte-macrophage lineage. Retrovirology 2010;7:32.
3. Perno CF, Newcomb FM, Davis DA, et al. Relative potency of protease inhibitors in mono-cytes/macrophages acutely and chronically infected with human immunodefciency virus. J Infect Dis 1998;178(2):413-422.
4. Aquaro S, Calio R, Balzarini J, et al. Macrophages and HIV infection: therapeutical approaches toward this strategic virus reservoir. Antiviral Res 2002;55(2):209-225.
5. Lambotte O, Taoufk Y, de Goer MG, et al. Detection of infectious HIV in circulating monocytes from patients on prolonged highly active antiretroviral therapy. J Acquir Immune Defc Syndr 2000;23(2):114-119.
6. Zhu T, Muthui D, Holte S, et al. Evidence for human immunodefciency virus type 1 replication in vivo in CD14(+) monocytes and its potential role as a source of virus in patients on highly active antiretroviral therapy. J Virol 2002;76(2):707-716.
7. Lamers SL, Salemi M, Galligan DC, et al. Extensive HIV-1 intra-host recombination is common in tissues with abnormal histopathology. PLoS One 2009;4(3):e5065.
8. Korber BT, Kunstman KJ, Patterson BK, et al. Genetic diferences between blood-and brain-derived viral sequences from human immunodefciency virus type 1-infected patients: evidence of conserved elements in the V3 region of the envelope protein of brain-derived sequences. J Virol 1994;68(11):7467-7481.
9. Shapshak P, Segal DM, Crandall KA, et al. Independent evolution of HIV type 1 in diferent brain regions. AIDS Res Hum Retroviruses 1999;15(9):811-820.
10. Williams KC, Corey S, Westmoreland SV, et al. Perivascular macrophages are the primary cell type productively infected by simian immunodefciency virus in the brains of macaques: implications for the neuropathogenesis of AIDS. J Exp Med 2001;193(8):905-915.
11. Almodovar S, Del CCM, Maldonado IM, et al. HIV-1 infection of monocytes is directly related to the success of HAART. Virology 2007;369(1):35-46.
12. Valcour VG, Shiramizu BT, Shikuma CM. HIV DNA in circulating monocytes as a mechanism to dementia and other HIV complications. J Leukoc Biol 2010;87(4):621-626.
13. Salemi M, Lamers SL, Huysentruyt LC, et al. Distinct patterns of HIV-1 evolution within metastatic tissues in patients with non-Hodgkins lymphoma. PLoS One 2009;4(12):e8153.
14. Novak RM, Richardson JT, Buchacz K, et al. Immune reconstitution infammatory syndrome: incidence and implications for mortality. AIDS 2012;26(6):721-730.
15. Achenbach CJ, Cole SR, Kitahata MM, et al. Mortality after cancer diagnosis in HIV-infected individuals treated with antiretroviral therapy. AIDS 2011;25(5):691-700.
16. Hogan C, Wilkins E. Neurological complications in HIV. Clin Med 2011;11(6):571-575.
17. McGrath MS. T-cells and macrophages in HIV disease. Clin Rev Allergy Immunol 1996;14(4):359-366.
18. Zack JA, Cann AJ, Lugo JP, Chen IS. HIV-1 production from infected peripheral blood T cells after HTLV-I induced mitogenic stimulation. Science 1988;240(4855):1026-1029.
19. Ho DD, Neumann AU, Perelson AS, et al. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995;373(6510):123-126.
20. Swingler S, Brichacek B, Jacque JM, et al. HIV-1 Nef intersects the macrophage CD40L signalling pathway to promote resting-cell infection. Nature 2003;424(6945):213-219.
21. Chan DJ. HIV-1 superinfection: evidence and impact. Curr HIV Res 2004;2(3):271-274.
22. Lindwasser OW, Chaudhuri R, Bonifacino JS. Mechanisms of CD4 downregulation by the Nef and Vpu proteins of primate immunodefciency viruses. Curr Mol Med 2007;7(2):171-184.
23. Olivetta E, Federico M. HIV-1 Nef protects human-monocyte-derived macrophages from HIV-1-induced apoptosis. Exp Cell Res 2006;312(6):890-900.
24. Swingler S, Mann AM, Zhou J, et al. Apoptotic killing of HIV-1-infected macrophages is subverted by the viral envelope glycoprotein. PLoS Pathog 2007;3(9):1281-1290.
25. Herbein G, Varin A. Te macrophage in HIV-1 infection: from activation to deactivation? Retrovi-rology 2010;7:33.
26. Mujawar Z, Rose H, Morrow MP, et al. Human immunodefciency virus impairs reverse cholesterol transport from macrophages. PLoS Biol 2006;4(11):e365.
27. Crowe SM, Westhorpe CL, Mukhamedova N, et al. Te macrophage: the intersection between HIV infection and atherosclerosis. J Leukoc Biol 2010;87(4):589-598.
28. Tsang J, Chain BM, Miller RF, et al. HIV-1 infection of macrophages is dependent on evasion of innate immune cellular activation. AIDS 2009 13;23(17):2255-2263.
29. Huysentruyt LC, McGrath MS. Te role of macrophages in the development and progression of AIDS-related non-Hodgkin lymphoma. J Leukoc Biol 2010;87(4):627-632.
30. Burke B, Lewis C. Te Macrophage. 2nd ed. Oxford: Oxford University Press; 2002.
31. Wraith DC, Nicholson LB. Te adaptive immune system in diseases of the central nervous system. J Clin Invest 2012;122(4):1172-1179.
32. Cassol E, Cassetta L, Alfano M, Poli G. Macrophage polarization and HIV-1 infection. J Leukoc Biol 2010;87(4):599-608.
33. Mantovani A, Sica A, Allavena P, et al. Tumor-associated macrophages and the related myeloid-derived suppressor cells as a paradigm of the diversity of macrophage activation. Hum Immunol 2009;70(5):325-330.
34. Sica A, Larghi P, Mancino A, et al. Macrophage polarization in tumour progression. Semin Cancer Biol 2008;18(5):349-355.
35. Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. Nat Rev Immunol 2008;8(12):958-969.
36. Piguet V, Trono D. Te Nef protein of primate lentiviruses. Rev Med Virol 1999;9(2):111-120.
37. Carl S, Greenough TC, Krumbiegel M, et al. Modulation of diferent human immunodefciency virus type 1 Nef functions during progression to AIDS. J Virol 2001;75(8):3657-3565.
38. Das SR, Jameel S. Biology of the HIV Nef protein. Indian J Med Res 2005;121(4):315-332.
39. Henao-MejiaJ, LiuY, Park IW, etal. SuppressionofHIV-1 Nef translationbySam68 mutant-induced stress granules and nef mRNA sequestration. Mol Cell 2009;33(1):87-96.
40. Schindler M, Munch J, Kutsch O, et al. Nef-mediated suppression of T cell activation was lost in a lentiviral lineage that gave rise to HIV-1. Cell 2006;125(6):1055-1067.
41. Foster JL, Garcia JV. HIV pathogenesis: Nef loses control. Cell 2006;125(6):1034-1035.
42. Robert-Gurof M, Popovic M, Gartner S, et al. Structure and expression of tat-, rev-, and nef-specifc transcripts of human immunodefciency virus type 1 in infected lymphocytes and macrophages. J Virol 1990;64(7):3391-3398.
43. Klotman ME, Kim S, Buchbinder A, et al. Kinetics of expression of multiply spliced RNA in early human immunodefciency virus type 1 infection of lymphocytes and monocytes. Proc Natl Acad Sci U S A 1991;88(11):5011-5015.
44. Choi HJ, Smithgall TE. Conserved residues in the HIV-1 Nef hydrophobic pocket are essential for recruitment and activation of the Hck tyrosine kinase. J Mol Biol 2004;343(5):1255-1268.
45. Lehmann MH, Walter S, Ylisastigui L, et al. Extracellular HIV-1 Nef increases migration of mono-cytes. Exp Cell Res 2006;312(18):3659-3668.
46. Ghiglione Y, Turk G. Nef performance in macrophages: the master orchestrator of viral persistence and spread. Curr HIV Res 2011;9(7):505-513.
47. Brown A, Moghaddam S, Kawano T, Cheng-Mayer C. Multiple human immunodefciency virus type 1 Nef functions contribute to efcient replication in primary human macrophages. J Gen Virol 2004;85(Pt 6):1463-1469.
48. Collins KL, Chen BK, Kalams SA, et al. HIV-1 Nef protein protects infected primary cells against killing by cytotoxic T lymphocytes. Nature 1998;391(6665):397-401.
49. Chaudhry A, Verghese DA, Das SR, et al. HIV-1 Nef promotes endocytosis of cell surface MHC class II molecules via a constitutive pathway. J Immunol 2009;183(4):2415-2424.
50. Peterlin BM, Trono D. Hide, shield and strike back: how HIV-infected cells avoid immune eradication. Nat Rev Immunol 2003;3(2):97-107.
51. Tachado SD, Li X, Swan K, et al. Constitutive activation of phosphatidylinositol 3-kinase signaling pathway down-regulates TLR4-mediated tumor necrosis factor-alpha release in alveolar macrophages from asymptomatic HIV-positive persons in vitro. J Biol Chem 2008;283(48):33191-33198.
52. Matsubara M, Jing T, Kawamura K, et al. Myristoyl moiety of HIV Nef is involved in regulation of the interaction with calmodulin in vivo. Protein Sci 2005;14(2):494-503.
53. Coleman CM, Spearman P, Wu L. Tetherin does not signifcantly restrict dendritic cell-mediated HIV-1 transmission and its expression is upregulated by newly synthesized HIV-1 Nef. Retrovirology 2011;8(1):26.
54. Schindler M, Rajan D, Banning C, et al. Vpu serine 52 dependent counteraction of tetherin is required for HIV-1 replication in macrophages, but not in ex vivo human lymphoid tissue. Retrovirol-ogy 2010;7:1.
55. Sauter D, Kirchhof F. Tetherin antagonism by primate lentiviral nef proteins. Curr HIV Res 2011;9(7):514-523.
56. Lee CH, Saksela K, Mirza UA, et al. Crystal structure of the conserved core of HIV-1 Nef complexed with a Src family SH3 domain. Cell 1996;85(6):931-942.
57. Herbein G, Gras G, Khan KA, Abbas W. Macrophage signaling in HIV-1 infection. Retrovirology 2010;7:34.
58. Costa LJ, Chen N, Lopes A, et al. Interactions between Nef and AIP1 proliferate multivesicular bodies and facilitate egress of HIV-1. Retrovirology 2006;3:33.
59. Lewis M, Lee P, Ng H, Yang O. Immune Selection in vitro reveals human immunodef-ciency virus-1 nef sequence motifs important for its immune evasion function in vivo. J Virol 2012;86(13):7126-7135.
60. Lewis MJ, Balamurugan A, Ohno A, et al. Functional adaptation of Nef to the immune milieu of HIV-1 infection in vivo. J Immunol 2008;180(6):4075-4081.
61. Poe JA, Smithgall TE. HIV-1 Nef dimerization is required for Nef-mediated receptor downregulation and viral replication. J Mol Biol 2009;394(2):329-342.
62. Bentham M, Mazaleyrat S, Harris M. Role of myristoylation and N-terminal basic residues in membrane association of the human immunodefciency virus type 1 Nef protein. J Gen Virol 2006;87(Pt 3):563-571.
63. Giese SI, Woerz I, Homann S, et al. Specifc and distinct determinants mediate membrane binding and lipid raft incorporation of HIV-1(SF2) Nef. Virology 2006;355(2):175-191.
64. Foster JL, Denial SJ, Temple BR, Garcia JV. Mechanisms of HIV-1 Nef Function and Intracellular Signaling. J Neuroimmune Pharmacol 2011;6(2):230-246.
65. Gerlach H, Laumann V, Martens S, et al. HIV-1 Nef membrane association depends on charge, curvature, composition and sequence. Nat Chem Biol 2010;6(1):46-53.
66. Coates K, Boulton V, Cooke S, et al. Analysis of the interactions between Nef and cellular proteins. Res Virol 1997;148(1):68-70.
67. Fackler OT, Kienzle N, Kremmer E, et al. Association of human immunodefciency virus Nef protein with actin is myristoylation dependent and infuences its subcellular localization. Eur J Biochem 1997;247(3):843-851.
68. Kaminchik J, Margalit R, Yaish S, et al. Cellular distribution of HIV type 1 Nef protein: identifcation of domains in Nef required for association with membrane and detergent-insoluble cellular matrix. AIDS Res Hum Retroviruses 1994;10(8):1003-1010.
69. Niederman TM, Hastings WR, Ratner L. Myristoylation-enhanced binding of the HIV-1 Nef protein to T cell skeletal matrix. Virology 1993;197(1):420-425.
70. Lenassi M, Cagney G, Liao M, et al. HIV Nef is secreted in exosomes and triggers apoptosis in bystander CD4+ T cells. Trafc 2010;11(1):110-122.
71. Shelton MN, Huang MB, Ali SA, et al. Secretion modifcation region-derived peptide disrupts HIV-1 Nef's interaction with mortalin and blocks virus and Nef exosome release. J Virol 2012;86(1):406-419.
72. Lamers SL, Fogel GB, Huysentruyt LC, McGrath MS. HIV-1 nef protein visits B-cells via macrophage nanotubes: a mechanism for AIDS-related lymphoma pathogenesis? Curr HIV Res 2010;8(8):638-640.
73. Xu W, Santini PA, Sullivan JS, et al. HIV-1 evades virus-specifc IgG2 and IgA responses by targeting systemic and intestinal B cells via long-range intercellular conduits. Nat Immunol 2009;10(9):1008-1017.
74. Rudnicka D, Schwartz O. Intrusive HIV-1-infected cells. Nat Immunol 2009;10(9):933-934.
75. Moir S, Fauci AS. Nef, macrophages and B cells: a highway for evasion. Immunol Cell Biol 2010;88(1):1-2.
76. Swingler S, Zhou J, Swingler C, et al. Evidence for a pathogenic determinant in HIV-1 Nef involved in B cell dysfunction in HIV/AIDS. Cell Host Microbe 2008;4(1):63-76.
77. Ng VL, Hurt MH, Herndier BG, et al. VH gene use by HIV type 1-associated lymphoproliferations. AIDS Res Hum Retroviruses 1997;13(2):135-149.
78. Herndier BG, Kaplan LD, McGrath MS. Pathogenesis of AIDS lymphomas. AIDS 1994;8(8):1025-1049.
79. Qiao X, He B, Chiu A, et al. Human immunodefciency virus 1 Nef suppresses CD40-dependent immunoglobulin class switching in bystander B cells. Nat Immunol 2006;7(3):302-310.
80. Lamers SL, Poon AF, McGrath MS. HIV-1 Nef protein structures associated with brain infection and dementia pathogenesis. PLoS One 2011;6(2):e16659.
81. Klein D, Hurley LB, Quesenberry CP, Jr., Sidney S. Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection? J Acquir Immune Defc Syndr 2002;30(5):471-477.
82. Currier JS, Lundgren JD, Carr A, et al. Epidemiological evidence for cardiovascular disease in HIV-infected patients and relationship to highly active antiretroviral therapy. Circulation 2008;118(2):e29-e35.
83. Hsue PY, Hunt PW, Schnell A, et al. Role of viral replication, antiretroviral therapy, and immunod-efciency in HIV-associated atherosclerosis. AIDS 2009;23(9):1059-1067.
84. Estrada V, Portilla J. Dyslipidemia related to antiretroviral therapy. AIDS Rev 2011;13(1):49-56.
85. Sprinz E, Lazzaretti RK, Kuhmmer R, Ribeiro JP. Dyslipidemia in HIV-infected individuals. Braz J Infect Dis 2010;14(6):575-588.
86. Onen NF, Overton ET.A reviewofpremature frailty in HIV-infected persons; another manifestation of HIV-related accelerated aging. Curr Aging Sci 2011;4(1):33-41.
87. Dressman J, Kincer J, Matveev SV, et al. HIV protease inhibitors promote atherosclerotic lesion formation independent of dyslipidemia by increasing CD36-dependent cholesteryl ester accumulation in macrophages. J Clin Invest 2003;111(3):389-397.
88. Hammond E, McKinnon E, Nolan D. Human immunodefciency virus treatment-induced adipose tissue pathology and lipoatrophy: prevalence and metabolic consequences. Clin Infect Dis 2010;51(5):591-599.
89. Burdo TH, Lo J, Abbara S, et al. Soluble CD163, a novel marker of activated macrophages, is elevated and associated with noncalcifed coronary plaque in HIV-infected patients. J Infect Dis 2011;204(8):1227-1236.
90. Asztalos BF, Mujawar Z, Morrow MP, et al. Circulating Nef induces dyslipidemia in simian immunodefciency virus-infected macaques by suppressing cholesterol efux. J Infect Dis 2010;202(4):614-623.
91. Linton MF, Fazio S. Macrophages, infammation, and atherosclerosis. Int J Obesity 2003;27(Suppl 3):S35-S40.
92. Salemi M, Lamers S, Yu S, et al. Phylodynamic analysis of human immunodefciency virus type 1 in distinct brain compartments provides a model for the neuropathogenesis of AIDS. J Virol 2005;79(17):11343-11352.
93. Williams K, Corey S, Westmoreland S, et al. Perivascular macrophages are the primary cell type productively infected by simian immunodefciency virus in the brains of macaques: implications for the neuropathogenesis of AIDS. J Exp Med 2001;193(8):905-916.
94. Williams KC, Hickey WF. Central nervous system damage, monocytes and macrophages, and neurological disorders in AIDS. Annu Rev Neurosci 2002;25:537-562.
95. Qin C, Nagao T, Grosheva I, et al. Elevated plasma membrane cholesterol content alters macrophage signaling and function. Arterioscler Tromb Vasc Biol 2006;26(2):372-378.
96. Nagao T, Qin C, Grosheva I, et al. Elevated cholesterol levels in the plasma membranes of macrophages inhibit migration by disrupting RhoA regulation. Arterioscler Tromb Vasc Biol 2007;27(7):1596-1602.
97. Llodra J, Angeli V, Liu J, et al. Emigration of monocyte-derived cells from atherosclerotic lesions characterizes regressive, but not progressive, plaques. Proc Natl Acad Sci USA 2004;101(32):11779-11784.
98. van't Wout AB, Swain JV, Schindler M, et al. Nef induces multiple genes involved in cholesterol synthesis and uptake in human immunodefciency virus type 1-infected T cells. J Virol 2005;79(15):10053-10058.
99. Morrow MP, Grant A, Mujawar Z, et al. Stimulation of the liver X receptor pathway inhibits HIV-1 replication via induction of ATP-binding cassette transporter A1. Mol Pharmacol 2010;78(2):215-225.
100. Koldamova R, Fitz NF, Lefterov I. Te role of ATP-binding cassette transporter A1 in Alzheimer's disease and neurodegeneration. Biochim Biophys Acta 2010;1801(8):824-830.
101. Suetani RJ, Sorrenson B, Tyndall JD, et al. Homology modeling and functional testing of an ABCA1 mutation causing Tangier disease. Atherosclerosis 2011;218(2):404-410.
102. Asztalos BF, Mujawar Z, Morrow MP, et al. Circulating Nef induces dyslipidemia in simian immunodefciency virus-infected macaques by suppressing cholesterol efux. J Infect Dis 2010;202(4):614-623.
103. Tsiodras S, Perelas A, Wanke C, Mantzoros CS. Te HIV-1/HAART associated metabolic syndrome-novel adipokines, molecular associations and therapeutic implications. J Infect 2010;61(2): 101-113.
104. Andersen O, Haugaard SB, Andersen UB, et al. Lipodystrophy in human immunodefciency virus patients impairs insulin action and induces defects in beta-cell function. Metabolism 2003;52(10):1343-1353.
105. Haugaard SB, Andersen O, Dela F, et al. Defective glucose and lipid metabolism in human immun-odefciency virus-infected patients with lipodystrophy involve liver, muscle tissue and pancreatic beta-cells. Eur J Endocrinol 2005;152(1):103-112.
106. Lamers SL, Salemi M, Galligan DC, et al. Human immunodefciency virus-1 evolutionary patterns associated with pathogenic processes in the brain. J Neurovirol 2010;16(3):230-241.
107. Snider WD, Simpson DM, Nielsen S, et al. Neurological complications of acquired immune def-ciency syndrome: analysis of 50 patients. Ann Neurol 1983;14(4):403-418.
108. Navia BA, Jordan BD, Price RW. Te AIDS dementia complex: I. Clinical features. Ann Neurol 1986;19(6):517-524.
109. Antinori A, Arendt G, Becker JT, et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology 2007;69(18):1789-1799.
110. Budka H. Te defnition of HIV-specifc neuropathology. Acta Pathol Jpn 1991;41(3):182-191.
111. Budka H, Costanzi G, Cristina S, etal. Brainpathologyinduced by infection with thehumanimmun-odefciency virus (HIV). A histological, immunocytochemical, and electron microscopical study of 100 autopsy cases. Acta Neuropathol 1987;75(2):185-198.
112. Budka H, Wiley CA, Kleihues P, et al. HIV-associated disease of the nervous system: review of nomenclature and proposal for neuropathology-based terminology. Brain Pathol 1991;1(3):143-152.
113. Pumarola-Sune T, Navia BA, Cordon-Cardo C, et al. HIV antigen in the brains of patients with the AIDS dementia complex. Ann Neurol 1987;21(5):490-496.
114. Grant I, Atkinson JH, Hesselink JR, et al. Evidence for early central nervous system involvement in the acquired immunodefciency syndrome (AIDS) and other human immunodefciency virus (HIV) infections. Studies with neuropsychologic testing and magnetic resonance imaging. Ann Intern Med 1987;107(6):828-836.
115. Glass JD, Fedor H, Wesselingh SL, McArthur JC. Immunocytochemical quantitation of human im-munodefciency virus in the brain: correlations with dementia. Ann Neurol 1995;38(5):755-762.
116. Masliah E, Heaton RK, Marcotte TD, et al. Dendritic injury is a pathological substrate for human immunodefciency virus-related cognitive disorders. HNRC Group. Te HIV Neurobehavioral Research Center. Ann Neurol 1997;42(6):963-972.
117. Bell JE. Te neuropathology of adult HIV infection. Rev Neurol (Paris) 1998;154(12):816-829.
118. Boni J, Emmerich BS, Leib SL, et al. PCR identifcation of HIV-1 DNA sequences in brain tissue of patients with AIDS encephalopathy. Neurology 1993;43(9):1813-1817.
119. Bhaskaran K, Mussini C, Antinori A, et al. Changes in the incidence and predictors of human im-munodefciency virus-associated dementia in the era of highly active antiretroviral therapy. Ann Neurol 2008;63(2):213-221.
120. Heaton RK, Cliford DB, Franklin DR, Jr., et al. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology 2010;75(23):2087-2096.
121. McArthur JC, McDermott MP, McClernon D, et al. Attenuated central nervous system infection in advanced HIV/AIDS with combination antiretroviral therapy. Arch Neurol 2004;61(11): 1687-1696.
122. Everall I, Vaida F, KhanlouN, etal. Cliniconeuropathologic correlates of human immunodefciency virus in the era of antiretroviral therapy. J Neurovirol 2009;15(5-6):360-370.
123. Cherner M, Masliah E, Ellis RJ, et al. Neurocognitive dysfunction predicts postmortem fndings of HIV encephalitis. Neurology 2002;59(10):1563- 1567.
124. Koedel U, Kohleisen B, Sporer B, et al. HIV type 1 Nef protein is a viral factor for leukocyte recruitment into the central nervous system. J Immunol 1999;163(3):1237-1245.
125. Annunziata P. Blood-brain barrier changes during invasion of the central nervous system by HIV-1. Old and new insights into the mechanism. J Neurol 2003;250(8):901-906.
126. Bergonzini V, Calistri A, Salata C, et al. Nef and cell signaling transduction: a possible involvement in the pathogenesis of human immunodefciency virus-associated dementia. J Neurovirol 2009;15(3):238-248.
127. Fiala M, Rhodes RH, Shapshak P, et al. Regulation of HIV-1 infection in astrocytes: expression of Nef, TNF-alpha and IL-6 is enhanced in coculture of astrocytes with macrophages. J Neurovirol 1996;2(3):158-166.
128. Lehmann MH, Masanetz S, Kramer S, Erfe V. HIV-1 Nef upregulates CCL2/MCP-1 expression in astrocytes in a myristoylation-and calmodulin-dependent manner. J Cell Sci 2006;119(Pt 21):4520-4530.
129. vanMarleG, HenryS, TodorukT, etal.Human immunodefciencyvirus type1Nefproteinmediates neural cell death: a neurotoxic role for IP-10. Virology 2004;329(2):302-318.
130. Davis LE, Hjelle BL, Miller VE, et al. Early viral brain invasion in iatrogenic human immunodef-ciency virus infection. Neurology 1992;42(9):1736-1739.
131. Georgsson G, Stahl-Hennig C, Tenner-Racz K, et al. Te central nervous system in mucosal vaccination of rhesus macaques with simian immunodefciency virus deltanef. Neuropathol Appl Neu-robiol 2007;33(6):644-657.
132. Alter G, Suscovich TJ, Teigen N, et al. Single-stranded RNA derived from HIV-1 serves as a potent activator of NK cells. J Immunol 2007;178(12):7658- 7666.
133. Zhao L, Galligan DC, Lamers SL, et al. High level HIV-1 DNA concentrations in brain tissues differentiate patients with post-HAART AIDS dementia complex or cardiovascular disease from those with AIDS. Sci China C Life Sci 2009;52(7):651-656.
134. Letendre S, Marquie-Beck J, Capparelli E, et al. Validation of the CNS penetration-efectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol 2008;65(1):65-70.
135. Harezlak J, Buchthal S, Taylor M, et al. Persistence of HIV-associated cognitive impairment, infammation, and neuronal injury in era of highly active antiretroviral treatment. AIDS 2011;25(5):625-633.
136. Bingham R, Ahmed N, Rangi P, et al. HIV encephalitis despite suppressed viraemia: a case of compartmentalized viral escape. Int J STD AIDS 2011;22(10):608-609.
137. Fischer-Smith T, Croul S, Sverstiuk AE, et al. CNS invasion by CD14+/CD16+ peripheral blood-derived monocytes in HIV dementia: perivascular accumulation and reservoir of HIV infection. J Neurovirol 2001;7(6):528-541.
138. Kumar S, Jack R. Origin of monocytes and their diferentiation to macrophages and dendritic cells. J Endotoxin Res 2006;12(5):278-284.
139. Williams K, Alvarez X, Lackner AA. Central nervous system perivascular cells are immunoregulatory cells that connect the CNS with the peripheral immune system. Glia 2001;36(2):156-164.
140. Pulliam L, Gascon R, Stubblebine M, et al. Unique monocyte subset in patients with AIDS dementia. Lancet 1997;349(9053):692-695.
141. Ancuta P, Kamat A, Kunstman KJ, et al. Microbial translocation is associated with increased mono-cyte activation and dementia in AIDS patients. PLoS One 2008;3(6):e2516.
142. Lyons JL, Uno H, Ancuta P, et al. Plasma sCD14 is a biomarker associated with impaired neurocog-nitive test performance in attention and learning domains in HIV infection. J Acquir Immune Defc Syndr 2011;57(5):371-379.
143. Strazza M, Pirrone V, Wigdahl B, Nonnemacher MR. Breaking down the barrier: the efects of HIV-1 on the blood-brain barrier. Brain Res 2011;1399:96-115.
144. Eugenin EA, Osiecki K, Lopez L, et al. CCL2/monocyte chemoattractant protein-1 mediates enhanced transmigration of human immunodefciency virus (HIV)-infected leukocytes across the blood-brain barrier: a potential mechanism of HIV-CNS invasion and neuroAIDS. J Neurosci 2006;26(4):1098-1106.
145. Eugenin EA, GamssR, Buckner C, etal. Shedding of PECAM-1 during HIV infection:a potential role for soluble PECAM-1 in the pathogenesis of neuroAIDS. J Leukoc Biol 2006;79(3):444-452.
146. MuratoriC, SistiguA, Ruggiero E, et al. Macrophages transmit human immunodefciency virus type 1 products to CD4-negative cells: involvement of matrix metalloproteinase 9. J virol [Research Support, Non-U.S. Gov't] 2007;81(17):9078-9087.
147. Zink MC, Brice AK, Kelly KM, etal. Simian immunodefciency virus-infected macaques treatedwith highly active antiretroviral therapy have reduced central nervous system viral replication and in-fammation but persistence of viral DNA. J Infect Dis 2010 ;202(1):161-170.
148. Bergamini A, Faggioli E, Bolacchi F, et al. Enhanced production of tumor necrosis factor-alpha and interleukin-6 due to prolonged response to lipopolysaccharide in human macrophages infected in vitro with human immunodefciency virus type 1. J Infect Dis 1999;179(4):832-842.
149. Brew BJ, Bhalla RB, Paul M, et al. Cerebrospinal fuid neopterin in human immunodefciency virus type 1 infection. Ann Neurol 1990;28(4):556-560.
150. Yao H, Bethel-Brown C, Li CZ, Buch SJ. HIV neuropathogenesis: a tight rope walk of innate immunity. J Neuroimmune Pharmacol [Research Support, N.I.H., Extramural Review] 2010;5(4): 489-495.
151. Sui Y, Stehno-Bittel L, Li S, et al. CXCL10-induced cell death in neurons: role of calcium dysregu-lation. Eur J Neurosci [Comparative Study Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't] 2006;23(4):957-964.
152. Smith DG, Guillemin GJ, Pemberton L, et al. Quinolinic acid is produced by macrophages stimulated by platelet activating factor, Nef and Tat. J Neurovirol [Research Support, Non-U.S. Gov't] 2001;7(1):56-60.
153. Xiong H, Zeng YC, Zheng J, et al. Soluble HIV-1 infected macrophage secretory products mediate blockade of long-term potentiation: a mechanism for cognitive dysfunction in HIV-1-associated dementia. J Neurovirol [In Vitro Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.] 1999;5(5):519-528.
154. Garden GA. Microglia in human immunodefciency virus-associated neurodegeneration. Glia 2002;40(2):240-251.
155. Gray F, Scaravilli F, Everall I, et al. Neuropathology of early HIV-1 infection. Brain Pathol 1996;6(1):1-15.
156. Meisner F, Neuen-Jacob E, Sopper S, et al. Disruption of excitatory amino acid transporters in brains of SIV-infected rhesus macaques is associated with microglia activation. J Neurochem 2008;104(1):202-209.
157. Rostasy K, Monti L, Yiannoutsos C, et al. Human immunodefciency virus infection, inducible nitric oxide synthase expression, and microglial activation: pathogenetic relationship to the acquired immunodefciency syndrome dementia complex. Ann Neurol [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.] 1999;46(2):207-216.
158. Field R, Campion S, Warren C, et al. Systemic challenge with the TLR3 agonist poly I:C induces amplifed IFN-alpha/beta and IL-1beta responses in the diseased brain and exacerbates chronic neurodegeneration. Brain Behav Immun 2010;24(6):996-1007.
159. Kitazawa M, Oddo S, Yamasaki TR, et al. Lipopolysaccharide-induced infammation exacerbates tau pathology by a cyclin-dependent kinase 5-mediated pathway in a transgenic model of Alzheimer's disease. J Neurosci 2005;25(39):8843-8853.
160. Gavett BE, Stern RA, McKee AC. Chronic traumatic encephalopathy: a potential late efect of sport-related concussive and subconcussive head trauma. Clin Sports Med 2011;30(1):179-188, xi.
161. Maccioni RB, Munoz JP, Barbeito L. Te molecular bases of Alzheimer's disease and other neurode-generative disorders. Arch Med Res 2001;32(5):367-381.
162. DeKosky ST, Ikonomovic MD, Gandy S. Traumatic brain injury-football, warfare, and long-term efects. N Engl J Med 2010;363(14):1293-1296.
163. Gisslen M, Krut J, Andreasson U, et al. Amyloid and tau cerebrospinal fuid biomarkers in HIV infection. BMC Neurol 2009;9:63.
164. Kadiu I, Nowacek A, McMillan J, Gendelman HE. Macrophage endocytic trafcking of antiretroviral nanoparticles. Nanomedicine (Lond) 2011;6(6):975-994.
165. Haughey NJ, Bandaru VV, Bae M, Mattson MP. Roles for dysfunctional sphingolipid metabolism in Alzheimer's disease neuropathogenesis. Biochim Biophys Acta 2010;1801(8):878-886.
166. Tompson KA, Kent SJ, Gahan ME, et al. Decreased neurotropism of nef long terminal repeat (nef/LTR)-deleted simian immunodefciency virus. J Neurovirol 2003;9(4):442-451.
167. Clarke S, Berry N, Ham C, et al. Neuropathology of wild-type and nef-attenuated T cell tropic simian immunodefciency virus (SIVmac32H) and macrophage tropic neurovirulent SIVmac17E-Fr in cynomolgus macaques. J Neurovirol 2012;18(2):100-112.
168. Werner T, Ferroni S, Saermark T, et al. HIV-1 Nefprotein exhibits structuraland functional similarity to scorpion peptides interacting with K+ channels. AIDS 1991;5(11):1301-1308.
169. Ranki A, Nyberg M, Ovod V, et al. Abundant expression of HIV Nef and Rev proteins in brain astrocytes in vivo is associated with dementia. AIDS [Research Support, Non-U.S. Gov't] 1995;9(9):1001-1008.
170. Mordelet E, Kissa K, Cressant A, et al. Histopathological and cognitive defects induced by Nef in the brain. FASEB J [Research Support, Non-U.S. Gov't] 2004;18(15):1851-1861.
171. Acheampong EA, Parveen Z, Muthoga LW, et al. Human immunodefciency virus type 1 Nef potently induces apoptosis in primary human brain microvascular endothelial cells via the activation of caspases. J virolo [Research Support, U.S. Gov't, P.H.S.] 2005;79(7):4257-4269.
172. Acheampong EA, Roschel C, Mukhtar M, et al. Combined efects of hyperglycemic conditions and HIV-1 Nef: a potential model for induced HIV neuropathogenesis. J Virol 2009;6:183.
173. Sporer B, Koedel U, Paul R, et al. Human immunodefciency virus type-1 Nef protein induces blood-brain barrier disruption in the rat: role of matrix metalloproteinase-9. J Neuroimmunol 2000;102(2):125-130.
174. Lama J. Te physiological relevance of CD4 receptor down-modulation during HIV infection. Curr HIV Res 2003;1(2):167-184.
175. Zheng J, Tylin MR, Ghorpade A, et al. Intracellular CXCR4 signaling, neuronal apoptosis and neuropathogenic mechanisms of HIV-1-associated dementia. J Neuroimmunol [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.] 1999;98(2):185-200.
176. Overholser ED, Coleman GD, Bennett JL, et al. Expression of simian immunodefciency virus (SIV) nef in astrocytes during acute and terminal infection and requirement of nef for optimal replication of neurovirulent SIV in vitro. J Virol [Research Support, U.S. Gov't, P.H.S.] 2003;77(12):6855-6866.
177. Olivetta E, Percario Z, Fiorucci G, et al. HIV-1 Nef induces the release of infammatory factors from human monocyte/macrophages: involvement of Nef endocytotic signals and NF-kappa B activation. J Immunol [Research Support, Non-U.S. Gov't] 2003;170(4):1716-1727.
178. Murray EA, Rausch DM, Lendvay J, et al. Cognitive and motor impairments associated with SIV infection in rhesus monkeys. Science 1992;255(5049):1246- 1249.
179. Sacktor N, Nakasujja N, Skolasky RL, et al. HIV subtype D is associated with dementia, compared with subtype A, in immunosuppressed individuals at risk of cognitive impairment in Kampala, Uganda. Clin Infect Dis 2009;49(5):780-786.
180. Salemi M, Lamers SL, Yu S, et al. Phylodynamic analysis of human immunodefciency virus type 1 in distinct brain compartments provides a model for the neuropathogenesis of AIDS. J Virol 2005;79(17):11343-11352.
181. Strickland SL, Gray RR, Lamers S, et al. Efcient transmission and persistence of low frequency SIVmac251 variants in CD8-depleted rhesus macaques with diferent neuropathology. J Gen Virol 2012;93(Pt 5):925-938.
182. Olivieri KC, Agopian KA, Mukerji J, Gabuzda D. Evidence for adaptive evolution at the divergence between lymphoid and brain HIV-1 nef genes. AIDS Res Hum Retroviruses 2010;26(4):495-500.
183. Gray LR, Gabuzda D, Cowley D, et al. CD4 and MHC class I down-modulation activities of nef alleles from brain-and lymphoid tissue-derived primary HIV-1 isolates. J Neurovirol 2011;17(1):82-91.
184. Singh DK, McCormick C, Pacyniak E, et al. A simian human immunodefciency virus with a nonfunctional Vpu (deltavpuSHIV(KU-1bMC33)) isolated from a macaque with neuroAIDS has selected for mutations in env and nef that contributed to its pathogenic phenotype. Virology 2001;282(1):123-140.
185. Brumme ZL, Brumme CJ, Heckerman D, et al. Evidence of diferential HLA class I-mediated viral evolution in functional and accessory/regulatory genes of HIV-1. PLoS Pathog 2007;3(7):e94.